Cellular Immunotherapy for Hematological Malignancies
A Special Issue of Cancers (ISSN 2072-6694) belonging to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 1 November 2026 | Viewed by 252
Editor
Special Issue Information
Dear Colleagues,
The therapeutic landscape of hematological malignancies has been profoundly transformed by the development of adoptive cell therapies. In particular, chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable efficacy in treating refractory B-cell malignancies and multiple myeloma. Despite these advances, important challenges remain, including variability in manufacturing outputs, limited persistence, immune escape mechanisms, and severe treatment-associated toxicities.
The identification and validation of robust translational biomarkers are essential to bridge the gap between product manufacturing, immune dynamics, and durable clinical responses. This Special Issue focuses on the intersection of product characterization, longitudinal immune profiling, and clinical outcomes, aiming to improve patient stratification, therapeutic monitoring, and outcome prediction. A deeper understanding of cellular fitness, host immune context, and molecular mechanisms of resistance is critical for advancing precision immunotherapy.
This Special Issue welcomes contributions addressing, but not limited to, the following areas:
- Innovative manufacturing platforms and their impact on cellular product functionality.
- High-dimensional immune profiling approaches (e.g., scRNA-seq, spectral flow cytometry) for monitoring in vivo expansion, persistence, and exhaustion.
- Predictive biomarkers for the early detection of toxicity and long-term clinical response.
- Mechanisms of resistance, including antigen loss and interactions with the immunosuppressive tumor microenvironment.
- The integration of multi-omics data and machine learning approaches to support personalized cellular immunotherapy.
By garnering advances across these domains, this Special Issue aims to provide a comprehensive framework for optimizing cellular immunotherapies, improving their safety, efficacy, and accessibility for patients with hematological malignancies.
Dr. Diego Carbonell
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cellular immunotherapy
- CAR-T cell therapy
- translational biomarkers
- immune monitoring
- cell manufacturing
- hematological malignancies
- clinical outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
